Pro-apoptotic  ||| S:0 E:14 ||| JJ
effects  ||| S:14 E:22 ||| NNS
of  ||| S:22 E:25 ||| IN
splice-switching  ||| S:25 E:42 ||| JJ
oligonucleotides  ||| S:42 E:59 ||| NNS
targeting  ||| S:59 E:69 ||| VBG
Bcl-x  ||| S:69 E:75 ||| JJ
pre-mRNA  ||| S:75 E:84 ||| NN
in  ||| S:84 E:87 ||| IN
human  ||| S:87 E:93 ||| JJ
glioma  ||| S:93 E:100 ||| JJ
cell  ||| S:100 E:105 ||| NN
lines  ||| S:105 E:111 ||| NNS
Alternative  ||| S:111 E:123 ||| JJ
splicing  ||| S:123 E:132 ||| NN
is  ||| S:132 E:135 ||| VBZ
a  ||| S:135 E:137 ||| DT
near-ubiquitous  ||| S:137 E:153 ||| JJ
phenomenon  ||| S:153 E:164 ||| NN
with  ||| S:164 E:169 ||| IN
important  ||| S:169 E:179 ||| JJ
roles  ||| S:179 E:185 ||| NNS
in  ||| S:185 E:188 ||| IN
human  ||| S:188 E:194 ||| JJ
diseases ||| S:194 E:202 ||| NNS
,  ||| S:202 E:204 ||| ,
including  ||| S:204 E:214 ||| VBG
cancers ||| S:214 E:221 ||| NNS
.  ||| S:221 E:223 ||| .
Splice-switching  ||| S:223 E:240 ||| JJ
oligonucleotides  ||| S:240 E:257 ||| NNS
( ||| S:257 E:258 ||| -LRB-
SSOs ||| S:258 E:262 ||| NNP
)  ||| S:262 E:264 ||| -RRB-
have  ||| S:264 E:269 ||| VBP
emerged  ||| S:269 E:277 ||| VBN
as  ||| S:277 E:280 ||| IN
a  ||| S:280 E:282 ||| DT
class  ||| S:282 E:288 ||| NN
of  ||| S:288 E:291 ||| IN
antisense  ||| S:291 E:301 ||| JJ
therapeutics  ||| S:301 E:314 ||| NN
that  ||| S:314 E:319 ||| WDT
modulate  ||| S:319 E:328 ||| VBP
alternative  ||| S:328 E:340 ||| JJ
splicing  ||| S:340 E:349 ||| NN
by  ||| S:349 E:352 ||| IN
hybridizing  ||| S:352 E:364 ||| VBG
to  ||| S:364 E:367 ||| TO
the  ||| S:367 E:371 ||| DT
pre-mRNA  ||| S:371 E:380 ||| JJ
splice  ||| S:380 E:387 ||| JJ
site ||| S:387 E:391 ||| NN
.  ||| S:391 E:393 ||| .
The  ||| S:393 E:397 ||| DT
Bcl-x  ||| S:397 E:403 ||| JJ
gene  ||| S:403 E:408 ||| NN
is  ||| S:408 E:411 ||| VBZ
alternatively  ||| S:411 E:425 ||| RB
spliced  ||| S:425 E:433 ||| VBN
to  ||| S:433 E:436 ||| TO
express  ||| S:436 E:444 ||| VB
anti‑apoptotic  ||| S:444 E:459 ||| NNP
Bcl-xL  ||| S:459 E:466 ||| NNP
and  ||| S:466 E:470 ||| CC
pro-apoptotic  ||| S:470 E:484 ||| JJ
Bcl-xS ||| S:484 E:490 ||| NN
.  ||| S:490 E:492 ||| .
Bcl-xL  ||| S:492 E:499 ||| JJ
expression  ||| S:499 E:510 ||| NN
is  ||| S:510 E:513 ||| VBZ
upregulated  ||| S:513 E:525 ||| VBN
in  ||| S:525 E:528 ||| IN
many  ||| S:528 E:533 ||| JJ
cancers  ||| S:533 E:541 ||| NNS
and  ||| S:541 E:545 ||| CC
is  ||| S:545 E:548 ||| VBZ
considered  ||| S:548 E:559 ||| VBN
a  ||| S:559 E:561 ||| DT
general  ||| S:561 E:569 ||| JJ
mechanism  ||| S:569 E:579 ||| NN
by  ||| S:579 E:582 ||| IN
which  ||| S:582 E:588 ||| WDT
cancer  ||| S:588 E:595 ||| NN
cells  ||| S:595 E:601 ||| NNS
evade  ||| S:601 E:607 ||| JJ
apoptosis ||| S:607 E:616 ||| NN
.  ||| S:616 E:618 ||| .
By  ||| S:618 E:621 ||| IN
redirecting  ||| S:621 E:633 ||| JJ
Bcl-x  ||| S:633 E:639 ||| JJ
pre-mRNA  ||| S:639 E:648 ||| JJ
splicing  ||| S:648 E:657 ||| NN
from  ||| S:657 E:662 ||| IN
Bcl-xL  ||| S:662 E:669 ||| JJ
to  ||| S:669 E:672 ||| TO
Bcl-xS ||| S:672 E:678 ||| JJ
,  ||| S:678 E:680 ||| ,
SSO  ||| S:680 E:684 ||| NNP
exerted  ||| S:684 E:692 ||| VBD
pro-apoptotic  ||| S:692 E:706 ||| JJ
and  ||| S:706 E:710 ||| CC
chemosensitizing  ||| S:710 E:727 ||| JJ
effects  ||| S:727 E:735 ||| NNS
in  ||| S:735 E:738 ||| IN
various  ||| S:738 E:746 ||| JJ
cancer  ||| S:746 E:753 ||| NN
cell  ||| S:753 E:758 ||| NN
lines ||| S:758 E:763 ||| NNS
.  ||| S:763 E:765 ||| .
In  ||| S:765 E:768 ||| IN
this  ||| S:768 E:773 ||| DT
study ||| S:773 E:778 ||| NN
,  ||| S:778 E:780 ||| ,
we  ||| S:780 E:783 ||| PRP
investigated  ||| S:783 E:796 ||| VBD
the  ||| S:796 E:800 ||| DT
effects  ||| S:800 E:808 ||| NNS
of  ||| S:808 E:811 ||| IN
SSO  ||| S:811 E:815 ||| NNP
targeting  ||| S:815 E:825 ||| VBG
Bcl-x  ||| S:825 E:831 ||| JJ
pre-mRNA  ||| S:831 E:840 ||| NN
in  ||| S:840 E:843 ||| IN
human  ||| S:843 E:849 ||| JJ
glioma  ||| S:849 E:856 ||| JJ
cell  ||| S:856 E:861 ||| NN
lines ||| S:861 E:866 ||| NNS
.  ||| S:866 E:868 ||| .
First ||| S:868 E:873 ||| NNP
,  ||| S:873 E:875 ||| ,
we  ||| S:875 E:878 ||| PRP
performed  ||| S:878 E:888 ||| VBD
reverse  ||| S:888 E:896 ||| RB
transcription-polymerase  ||| S:896 E:921 ||| JJ
chain  ||| S:921 E:927 ||| NN
reaction  ||| S:927 E:936 ||| NN
( ||| S:936 E:937 ||| -LRB-
RT-PCR ||| S:937 E:943 ||| NNP
)  ||| S:943 E:945 ||| -RRB-
and  ||| S:945 E:949 ||| CC
western  ||| S:949 E:957 ||| JJ
blotting  ||| S:957 E:966 ||| NN
to  ||| S:966 E:969 ||| TO
determine  ||| S:969 E:979 ||| VB
the  ||| S:979 E:983 ||| DT
mRNA  ||| S:983 E:988 ||| JJ
and  ||| S:988 E:992 ||| CC
protein  ||| S:992 E:1000 ||| NN
expression  ||| S:1000 E:1011 ||| NN
levels  ||| S:1011 E:1018 ||| NNS
of  ||| S:1018 E:1021 ||| IN
Bcl-xL  ||| S:1021 E:1028 ||| JJ
in  ||| S:1028 E:1031 ||| IN
glioma  ||| S:1031 E:1038 ||| JJ
cell  ||| S:1038 E:1043 ||| NN
lines  ||| S:1043 E:1049 ||| NNS
( ||| S:1049 E:1050 ||| -LRB-
U87  ||| S:1050 E:1054 ||| NNP
and  ||| S:1054 E:1058 ||| CC
U251 ||| S:1058 E:1062 ||| CD
)  ||| S:1062 E:1064 ||| -RRB-
and  ||| S:1064 E:1068 ||| CC
a  ||| S:1068 E:1070 ||| DT
normal  ||| S:1070 E:1077 ||| JJ
human  ||| S:1077 E:1083 ||| JJ
astrocyte  ||| S:1083 E:1093 ||| JJ
cell  ||| S:1093 E:1098 ||| NN
line  ||| S:1098 E:1103 ||| NN
( ||| S:1103 E:1104 ||| -LRB-
HA1800 ||| S:1104 E:1110 ||| NNP
) ||| S:1110 E:1111 ||| -RRB-
.  ||| S:1111 E:1113 ||| .
Then ||| S:1113 E:1117 ||| RB
,  ||| S:1117 E:1119 ||| ,
the  ||| S:1119 E:1123 ||| DT
Bcl-x  ||| S:1123 E:1129 ||| JJ
SSO  ||| S:1129 E:1133 ||| NNP
was  ||| S:1133 E:1137 ||| VBD
designed  ||| S:1137 E:1146 ||| VBN
to  ||| S:1146 E:1149 ||| TO
bind  ||| S:1149 E:1154 ||| VB
to  ||| S:1154 E:1157 ||| TO
the  ||| S:1157 E:1161 ||| DT
downstream  ||| S:1161 E:1172 ||| JJ
5 ||| S:1172 E:1173 ||| CD
'  ||| S:1173 E:1175 ||| POS
alternative  ||| S:1175 E:1187 ||| JJ
splice  ||| S:1187 E:1194 ||| JJ
site  ||| S:1194 E:1199 ||| NN
of  ||| S:1199 E:1202 ||| IN
exon 2  ||| S:1202 E:1209 ||| CD
in  ||| S:1209 E:1212 ||| IN
Bcl-x  ||| S:1212 E:1218 ||| JJ
pre-mRNA  ||| S:1218 E:1227 ||| JJ
and  ||| S:1227 E:1231 ||| CC
was  ||| S:1231 E:1235 ||| VBD
modified  ||| S:1235 E:1244 ||| VBN
using  ||| S:1244 E:1250 ||| VBG
2 ||| S:1250 E:1251 ||| CD
' ||| S:1251 E:1252 ||| POS
-O-methoxyethyl-phosphorothioate ||| S:1252 E:1284 ||| JJ
.  ||| S:1284 E:1286 ||| .
An  ||| S:1286 E:1289 ||| DT
oligonucleotide  ||| S:1289 E:1305 ||| NN
targeting  ||| S:1305 E:1315 ||| VBG
aberrantly  ||| S:1315 E:1326 ||| JJ
spliced  ||| S:1326 E:1334 ||| JJ
human  ||| S:1334 E:1340 ||| JJ
β-globin  ||| S:1340 E:1349 ||| JJ
intron  ||| S:1349 E:1356 ||| NN
was  ||| S:1356 E:1360 ||| VBD
used  ||| S:1360 E:1365 ||| VBN
as  ||| S:1365 E:1368 ||| IN
a  ||| S:1368 E:1370 ||| DT
negative  ||| S:1370 E:1379 ||| JJ
control ||| S:1379 E:1386 ||| NN
.  ||| S:1386 E:1388 ||| .
The  ||| S:1388 E:1392 ||| DT
SSOs  ||| S:1392 E:1397 ||| NN
were  ||| S:1397 E:1402 ||| VBD
delivered  ||| S:1402 E:1412 ||| VBN
with  ||| S:1412 E:1417 ||| IN
a  ||| S:1417 E:1419 ||| DT
cationic  ||| S:1419 E:1428 ||| JJ
lipid  ||| S:1428 E:1434 ||| NN
into  ||| S:1434 E:1439 ||| IN
glioma  ||| S:1439 E:1446 ||| NN
and  ||| S:1446 E:1450 ||| CC
astrocyte  ||| S:1450 E:1460 ||| JJ
cell  ||| S:1460 E:1465 ||| NN
lines ||| S:1465 E:1470 ||| NNS
.  ||| S:1470 E:1472 ||| .
The  ||| S:1472 E:1476 ||| DT
antitumor  ||| S:1476 E:1486 ||| JJ
effects  ||| S:1486 E:1494 ||| NNS
of  ||| S:1494 E:1497 ||| IN
the  ||| S:1497 E:1501 ||| DT
SSOs  ||| S:1501 E:1506 ||| NN
were  ||| S:1506 E:1511 ||| VBD
assessed  ||| S:1511 E:1520 ||| VBN
by  ||| S:1520 E:1523 ||| IN
3- ||| S:1523 E:1525 ||| NNP
( ||| S:1525 E:1526 ||| -LRB-
4,5-dimethylthiazol-2-yl ||| S:1526 E:1550 ||| NNP
) ||| S:1550 E:1551 ||| -RRB-
-2,5-diphenyltetrazolium  ||| S:1551 E:1576 ||| FW
bromide  ||| S:1576 E:1584 ||| FW
assays  ||| S:1584 E:1591 ||| FW
and  ||| S:1591 E:1595 ||| CC
flow  ||| S:1595 E:1600 ||| NN
cytometry ||| S:1600 E:1609 ||| NN
,  ||| S:1609 E:1611 ||| ,
and  ||| S:1611 E:1615 ||| CC
the  ||| S:1615 E:1619 ||| DT
switch  ||| S:1619 E:1626 ||| NN
in  ||| S:1626 E:1629 ||| IN
production  ||| S:1629 E:1640 ||| NN
from  ||| S:1640 E:1645 ||| IN
Bcl-xL  ||| S:1645 E:1652 ||| JJ
to  ||| S:1652 E:1655 ||| TO
Bcl-xS  ||| S:1655 E:1662 ||| NNP
was  ||| S:1662 E:1666 ||| VBD
analyzed  ||| S:1666 E:1675 ||| VBN
by  ||| S:1675 E:1678 ||| IN
RT-PCR  ||| S:1678 E:1685 ||| JJ
and  ||| S:1685 E:1689 ||| CC
western  ||| S:1689 E:1697 ||| JJ
blotting ||| S:1697 E:1705 ||| NN
.  ||| S:1705 E:1707 ||| .
Bcl-xL  ||| S:1707 E:1714 ||| NNP
mRNA  ||| S:1714 E:1719 ||| NNP
and  ||| S:1719 E:1723 ||| CC
protein  ||| S:1723 E:1731 ||| NN
were  ||| S:1731 E:1736 ||| VBD
highly  ||| S:1736 E:1743 ||| RB
expressed  ||| S:1743 E:1753 ||| VBN
in  ||| S:1753 E:1756 ||| IN
both  ||| S:1756 E:1761 ||| DT
glioma  ||| S:1761 E:1768 ||| JJ
cell  ||| S:1768 E:1773 ||| NN
lines ||| S:1773 E:1778 ||| NNS
.  ||| S:1778 E:1780 ||| .
The  ||| S:1780 E:1784 ||| DT
Bcl-x  ||| S:1784 E:1790 ||| JJ
SSO  ||| S:1790 E:1794 ||| NNS
modified  ||| S:1794 E:1803 ||| VBN
Bcl-x  ||| S:1803 E:1809 ||| JJ
pre-mRNA  ||| S:1809 E:1818 ||| JJ
splicing  ||| S:1818 E:1827 ||| NN
and  ||| S:1827 E:1831 ||| CC
had  ||| S:1831 E:1835 ||| VBD
pro-apoptotic  ||| S:1835 E:1849 ||| JJ
effects  ||| S:1849 E:1857 ||| NNS
on  ||| S:1857 E:1860 ||| IN
the  ||| S:1860 E:1864 ||| DT
glioma  ||| S:1864 E:1871 ||| JJ
cell  ||| S:1871 E:1876 ||| NN
lines ||| S:1876 E:1881 ||| NNS
.  ||| S:1881 E:1883 ||| .
By  ||| S:1883 E:1886 ||| IN
contrast ||| S:1886 E:1894 ||| NN
,  ||| S:1894 E:1896 ||| ,
the  ||| S:1896 E:1900 ||| DT
lipid  ||| S:1900 E:1906 ||| NN
alone  ||| S:1906 E:1912 ||| RB
and  ||| S:1912 E:1916 ||| CC
the  ||| S:1916 E:1920 ||| DT
control  ||| S:1920 E:1928 ||| NN
SSO  ||| S:1928 E:1932 ||| NNP
did  ||| S:1932 E:1936 ||| VBD
not  ||| S:1936 E:1940 ||| RB
affect  ||| S:1940 E:1947 ||| VB
Bcl-xL  ||| S:1947 E:1954 ||| JJ
expression  ||| S:1954 E:1965 ||| NN
or  ||| S:1965 E:1968 ||| CC
induce  ||| S:1968 E:1975 ||| VB
apoptosis ||| S:1975 E:1984 ||| NNS
.  ||| S:1984 E:1986 ||| .
Our  ||| S:1986 E:1990 ||| PRP$
study  ||| S:1990 E:1996 ||| NN
demonstrated  ||| S:1996 E:2009 ||| VBD
the  ||| S:2009 E:2013 ||| DT
antitumor  ||| S:2013 E:2023 ||| JJ
activity  ||| S:2023 E:2032 ||| NN
of  ||| S:2032 E:2035 ||| IN
an  ||| S:2035 E:2038 ||| DT
SSO  ||| S:2038 E:2042 ||| NN
that  ||| S:2042 E:2047 ||| WDT
targets  ||| S:2047 E:2055 ||| VBZ
Bcl-x  ||| S:2055 E:2061 ||| JJ
pre-mRNA  ||| S:2061 E:2070 ||| JJ
splicing  ||| S:2070 E:2079 ||| NN
in  ||| S:2079 E:2082 ||| IN
glioma  ||| S:2082 E:2089 ||| JJ
cell  ||| S:2089 E:2094 ||| NN
lines ||| S:2094 E:2099 ||| NNS
.  ||| S:2099 E:2101 ||| .
Bcl-x  ||| S:2101 E:2107 ||| NNP
SSO  ||| S:2107 E:2111 ||| NNP
may  ||| S:2111 E:2115 ||| MD
be  ||| S:2115 E:2118 ||| VB
a  ||| S:2118 E:2120 ||| DT
potential  ||| S:2120 E:2130 ||| JJ
strategy  ||| S:2130 E:2139 ||| NN
for  ||| S:2139 E:2143 ||| IN
treating  ||| S:2143 E:2152 ||| VBG
gliomas ||| S:2152 E:2159 ||| NNS
.  ||| S:2159 E:2161 ||| .
